U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07221656) titled 'Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration' on Oct. 24.
Brief Summary: This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Study Start Date: Nov. 01
Study Type: OBSERVATIONAL
Condition:
Childhood Acute Lymphoblastic Leukemia
Childhood Lymphoblastic Lymphoma
Intervention:
OTHER: Non-Interventional Study
Non-inter...